Proposed US Tariffs Threaten Progress of India Trade Deal

• New punitive US tariff initiatives are threatening to derail the ongoing India-US trade agreement negotiations.
• The friction stems from US legislation targeting Russian energy ties and administrative mandates requiring the reshoring of generic pharmaceutical production.

Sanctions and Energy Trade

• The bipartisan 'Lindsey O. Graham Sanctioning Russia and Iran Act of 2026' proposes 100% tariffs on goods from the world's five largest importers of Russian crude oil and natural gas.
• As the second-largest buyer of Russian crude, India faces significant exposure to these penalties.
• India's dependence on Russian crude surged to 43% of total imports in the first half of 2026, while imports from the US declined significantly, heightening US-India trade tensions.

Pharmaceutical Reshoring Pressures

• President Trump has announced a plan to impose 100% tariffs on generic medicines starting in 2028, rising to 200% by 2029, to force companies to relocate production to the US.
• The US is the largest export market for Indian pharmaceutical companies, with many firms relying on the US for up to 50% of their total sales.
• Major Indian pharmaceutical players, including Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Life Sciences, have already committed over $19.1 billion in US investments to mitigate the impact of these proposed tariffs.